<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979572</url>
  </required_header>
  <id_info>
    <org_study_id>TS172-101</org_study_id>
    <nct_id>NCT04979572</nct_id>
  </id_info>
  <brief_title>A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)</brief_title>
  <official_title>A Phase 1, Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending and Multiple Dose of TS-172 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the&#xD;
      Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending and Multiple Dose of&#xD;
      TS-172 in Healthy Adult Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) and serious AEs (SAEs)</measure>
    <time_frame>Part A (Step 1): Day 1 up to Day 8, Part A (Step 2, 3, 4): Day 1 up to Day 4, Part B: Day 1 up to Day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of unchanged form in plasma, urine and stool</measure>
    <time_frame>Part A: Day 1 up to Day 4, Part B: Day 1 up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of unchanged form</measure>
    <time_frame>Part A: Day 1 up to Day 4, Part B: Day 1 up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean daily urinaly excretion of sodium and phosphorus</measure>
    <time_frame>Part A (Step 1): Day 1 up to Day 8, Part A (Step 2, 3, 4): Day 1 up to Day 4, Part B: Day 1 up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean daily Bristol Stool Form Scale (BSFS)</measure>
    <time_frame>Part A (Step 1): Day 1 up to Day 8, Part A (Step 2, 3, 4): Day 1 up to Day 4, Part B: Day 1 up to Day 11</time_frame>
    <description>BSFS is a scale between 1-7, where 1 correlates with the firmest stool and 7 correlates with entirely liquid stool</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>Part A (single dose) : Step 1 to 4: TS-172 10 mg, 30 mg, 90 mg, 270 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of TS-172 or placebo before breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (multiple dose) : Step 5: TS-172 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose of TS-172 or placebo before breakfast and dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-172</intervention_name>
    <description>Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)&#xD;
Multiple dose of TS-172 90 mg before breakfast and dinner</description>
    <arm_group_label>Part A (single dose) : Step 1 to 4: TS-172 10 mg, 30 mg, 90 mg, 270 mg</arm_group_label>
    <arm_group_label>Part B (multiple dose) : Step 5: TS-172 90 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)&#xD;
Multiple dose of TS-172 placebo before breakfast and dinner</description>
    <arm_group_label>Part A (single dose) : Step 1 to 4: TS-172 10 mg, 30 mg, 90 mg, 270 mg</arm_group_label>
    <arm_group_label>Part B (multiple dose) : Step 5: TS-172 90 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Japanese healthy males aged 20 years or older but less than 40 years at the time of&#xD;
             informed consent&#xD;
&#xD;
          2. Those with a BMI of 18.5 or more and less than 25.0 at screening test&#xD;
&#xD;
          3. Those who are able to receive the explanation before participating in the study,&#xD;
             understand the content of the study, and provide written informed consent by the&#xD;
             subjects themselves.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have any disease and are not considered healthy subjects based on the&#xD;
             medical judgment of the principal investigator or sub-investigator.&#xD;
&#xD;
          2. Those who correspond to any of the following about bowel movements;&#xD;
&#xD;
               -  Repeated diarrhea (Bristol Stool Form Score [BSFS] score of 6 or higher) on a&#xD;
                  daily basis&#xD;
&#xD;
               -  Repeated constipation (no defecation for 2 days or more in a week) on a daily&#xD;
                  basis&#xD;
&#xD;
          3. Those who correspond to any of the following about bowel movements in the 7 days&#xD;
             before administration;&#xD;
&#xD;
               -  Diarrhea on 2 or more days in 7 days&#xD;
&#xD;
               -  2 or more days without a bowel movement in 7 days&#xD;
&#xD;
          4. Those who have a history of gastrointestinal ulceration&#xD;
&#xD;
          5. Those who correspond to any of the following about infection;&#xD;
&#xD;
               -  Positive for SARS-CoV-2 in the nucleic acid amplification test performed at the&#xD;
                  time of admission&#xD;
&#xD;
               -  Suspected of having COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisho Director</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taisho Pharmaceutical Co., Ltd.</last_name>
    <phone>81-3-3985-1413</phone>
    <email>clinical-trials_CTG@taisho.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Toshima-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taisho Direcotor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

